The LongevityShow made longevity look less like a niche and more like an operating system

The LongevityShow made longevity look less like a niche and more like an operating system

The LongevityShow — the UK’s first festival dedicated entirely to the science and practice of extending healthspan — took over Tobacco Dock in East London, bringing together 150 speakers and more than 100 organisations from across medicine, biotechnology, nutrition science, diagnostics, AI and personalised health. The standout tools were not vibes: biological age testing measuring hundreds of biomarkers across multiple organ systems, continuous glucose monitoring making metabolic health visible in real time, AI platforms identifying chronic disease risk years — sometimes decades — before onset, precision nutrition protocols built from individual gene expression, and microbiome analysis revealing each person’s inner ecosystem. The bigger thesis was blunt: healthspan is becoming a science in its own right, but the deeper question that no diagnostic panel can fully illuminate is not how long, but how and for what we are living longer.

Gobble's Take: When the expo can make your body feel legible in real time, “wait and see” starts looking prehistoric.
Source: The Longevity Revolution

Peptides are leaving the gray zone and heading straight into the FDA spotlight

For years, peptides have existed in one of medicine’s grayest zones: embraced by longevity physicians, dismissed by skeptics, promoted by influencers, compounded by specialty pharmacies, and purchased from anonymous websites around the world. Now the upcoming meeting of the FDA’s Pharmacy Compounding Advisory Committee is being framed as one of the most important inflection points the peptide field has faced. The article pointedly says this is not about whether BPC-157 works or whether MOTS-c becomes the next breakthrough in metabolic medicine; it’s about who gets to decide whether these therapies belong in modern medicine.

Gobble's Take: The peptide era was always going to end up in front of a referee; the only question was how long the warmup would last.
Source: How the FDA Could Redraw the Future of Longevity Medicine

Longevity’s favorite rule is now “it depends”

The most persistent signal across this cycle’s episodes is the death of one-size-fits-all medicine and the rise of N-of-1. The Longevity Digest frames the future of longevity care as matching the right intervention to the right patient at the right time using multi-omic layering, moving from ApoB and CRP to biomarkers like MMP-9, TGF-β1, homocysteine, and C4a. It also highlights autonomic modulation — specifically vagal nerve stimulation to suppress the NLRP3 inflammasome via the cholinergic anti-inflammatory pathway — as a high-leverage, low-cost lever sitting inside every practice.

Gobble's Take: Personalized longevity keeps winning because generic medicine is starting to look like a blunt instrument in a world asking for a scalpel.
Source: The Longevity Digest 06/17 - 06/29

In Case You Missed It

Yesterday's top stories:

• Ryan Cole, the "immortality elixir," and a very public flip
• Life Bio, partial epigenetic reprogramming, and the first human test